Lexicon Pharmaceutcl (LXRX) Stock Price, Quote & News

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 863 3000

Fax: 281 863 8088

Website: www.lexpharma.com

Address:

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

Jbjb90 Jul. 12 at 3:00 AM

$LXRX https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/lexicon-pharmaceuticals-incs-nasdaqlxrx-market-cap-touched-u/amp

0 · Reply

Ihuarraqax123 Jul. 11 at 11:13 PM

$LXRX 7 days more;) cross the fingers;)

1 · Reply

Thekareemofthecrop Jul. 11 at 9:47 PM

$LXRX

0 · Reply

epk1970 Jul. 11 at 9:08 PM

$LXRX let's see..... starting the week hovering in the $0.90s wondering if we can crack $1, to hoping we can make it through the usual Friday sell off and stay around $1.10...... now that's a complete change of situation in a short time period. Very nice.... especially considering we made it through Friday with a nice cushion above $1. Shows me we may have some staying power....

0 · Reply

Keywest20 Jul. 11 at 9:05 PM

$LXRX good luck, brother. Hope you have a great weekend. Maybe I’ll talk to you on Monday.

1 · Reply

minybombayprincess Jul. 11 at 8:33 PM

$LXRX As long as it stays over a dollar with some stability, then I'm happy. I just wanted some stocks that I can afford and not have to keep a constant eye on. I'm not a real trader, just thinking about my future.

0 · Reply

SPARTANWHITE22 Jul. 11 at 8:26 PM

$LXRX Do not underestimate what we have accomplished this week...Great weekend to those that made it possible...

0 · Reply

Z12 Jul. 11 at 8:21 PM

$LXRX Up 21% on the week, I can live with a 4% breather. Lets just keep banging those over $1 closes in!

0 · Reply

Dooright Jul. 11 at 8:04 PM

$LXRX T-7! 😆 Doc C. 🤓

0 · Reply

Jbjb90 Jul. 11 at 8:02 PM

$LXRX 3 down, 7 to go and then its full speed ahead with all the nonsense behind us

0 · Reply

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 8:30 AM EDT - 23 days ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

May 29, 2025, 8:00 AM EDT - 6 weeks ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 7 weeks ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 13, 2025, 9:47 PM EDT - 2 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:00 PM EDT - 2 months ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 2 months ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 2 months ago

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 25, 2025, 9:00 AM EDT - 2 months ago

Top 2 Health Care Stocks That May Crash This Month

Apr 2, 2025, 8:00 AM EDT - 3 months ago

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 28, 2025, 10:09 AM EDT - 3 months ago

Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal

NVO

Mar 28, 2025, 9:02 AM EDT - 3 months ago

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk

NVO

Mar 28, 2025, 7:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Mar 7, 2025, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

Mar 6, 2025, 10:52 PM EST - 4 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:00 PM EST - 4 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 4, 2025, 4:15 PM EST - 4 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Mar 3, 2025, 7:00 AM EST - 4 months ago

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Mar 2, 2025, 4:13 PM EST - 4 months ago

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Feb 18, 2025, 8:00 AM EST - 5 months ago

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Jan 21, 2025, 8:00 AM EST - 6 months ago

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Jan 2, 2025, 8:00 AM EST - 6 months ago

Lexicon Appoints Scott Coiante as Chief Financial Officer

Dec 20, 2024, 4:46 PM EST - 7 months ago

US FDA declines to approve Lexicon Pharma's add-on diabetes drug

Dec 20, 2024, 4:30 PM EST - 7 months ago

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Nov 26, 2024, 8:00 AM EST - 8 months ago

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Nov 25, 2024, 4:15 PM EST - 8 months ago

Lexicon Pharmaceuticals to Participate in December Investor Conferences

Nov 22, 2024, 7:47 AM EST - 8 months ago

Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development

Nov 22, 2024, 7:32 AM EST - 8 months ago

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

Nov 20, 2024, 4:05 PM EST - 8 months ago

Lexicon Appoints Ivan H. Cheung to Board of Directors

Nov 12, 2024, 8:39 PM EST - 8 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 8 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 8:00 AM EST - 8 months ago

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

Nov 5, 2024, 4:05 PM EST - 8 months ago

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

Oct 31, 2024, 6:54 PM EDT - 9 months ago

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

Oct 31, 2024, 4:54 PM EDT - 9 months ago

FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes

Oct 16, 2024, 4:35 PM EDT - 9 months ago

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

Oct 16, 2024, 4:34 PM EDT - 9 months ago

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

VTRS

Sep 27, 2024, 8:00 AM EDT - 10 months ago

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Sep 16, 2024, 8:00 AM EDT - 10 months ago

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

Sep 10, 2024, 8:00 AM EDT - 10 months ago

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Sep 3, 2024, 4:00 PM EDT - 11 months ago

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 13, 2024, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

Aug 3, 2024, 6:29 AM EDT - 1 year ago

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 1, 2024, 11:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

Jul 8, 2024, 9:15 AM EDT - 1 year ago

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

Jun 19, 2024, 8:00 AM EDT - 1 year ago

Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Jun 14, 2024, 8:00 AM EDT - 1 year ago

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

Jbjb90 Jul. 12 at 3:00 AM

$LXRX https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/lexicon-pharmaceuticals-incs-nasdaqlxrx-market-cap-touched-u/amp

0 · Reply

Ihuarraqax123 Jul. 11 at 11:13 PM

$LXRX 7 days more;) cross the fingers;)

1 · Reply

Thekareemofthecrop Jul. 11 at 9:47 PM

$LXRX

0 · Reply

epk1970 Jul. 11 at 9:08 PM

0 · Reply

Keywest20 Jul. 11 at 9:05 PM

$LXRX good luck, brother. Hope you have a great weekend. Maybe I’ll talk to you on Monday.

1 · Reply

minybombayprincess Jul. 11 at 8:33 PM

0 · Reply

SPARTANWHITE22 Jul. 11 at 8:26 PM

$LXRX Do not underestimate what we have accomplished this week...Great weekend to those that made it possible...

0 · Reply

Z12 Jul. 11 at 8:21 PM

$LXRX Up 21% on the week, I can live with a 4% breather. Lets just keep banging those over $1 closes in!

0 · Reply

Dooright Jul. 11 at 8:04 PM

$LXRX T-7! 😆 Doc C. 🤓

0 · Reply

Jbjb90 Jul. 11 at 8:02 PM

$LXRX 3 down, 7 to go and then its full speed ahead with all the nonsense behind us

0 · Reply

LionNoRichy Jul. 11 at 8:00 PM

$LXRX 7 more

0 · Reply

SniperPro Jul. 11 at 7:11 PM

🔥WHAT A WEEK AND IS NOT OVER YET.... BOOOM 🔥 $ABVE 118% $FTFT 118% $WKHS 72% $INKT 800% $LXRX 30% $INKT $7.70 TO $71 IF YOU THINK HOLDING IS FOR WIMPS, YOU DON'T KNOW JACK!

2 · Reply

KurwaMac Jul. 11 at 7:06 PM

$LXRX sometimes it takes a long time before pps catches up to potential value of the company, but sometimes it happens in a blitz.

0 · Reply

CharlyBue Jul. 11 at 6:40 PM

$LXRX damn offers, should forbidden, foolish Wall Street 🤮

0 · Reply

GenericPoster Jul. 11 at 5:37 PM

$LXRX For what it is worth, I had the last remaining shares returned today from the shorts. Yesterday, I had July options exercise early which almost never happens unless there is a dividend involved. So, these two actions and the lower cost of borrowing shares now show the short is covering. And, as I posted last evening, there were 4.36 million fewer shares short at the end of June as compared to the prior mid-June report leaving 33.2 million shares short as of the end of June.

1 · Reply

Achouffe Jul. 11 at 5:26 PM

$LXRX Buy Some more, evt we’ll get there

1 · Reply

beezee8 Jul. 11 at 5:24 PM

$LXRX

0 · Reply

brenlabs_on_twitch Jul. 11 at 5:22 PM

$LXRX ayoooo

0 · Reply

Dooright Jul. 11 at 4:52 PM

$LXRX T minus 8 (T-8) in our countdown. Hopefully, nothing stupid happens and we achieve liftoff on July 22nd. If we have to reset, so be it, but I’m staying positive about it. We have plenty of time left and IT’S ALL GOOD. Hold, hold, hold and buy, buy, buy! Doc C. 🤓

1 · Reply

macrossluvsrobotech Jul. 11 at 4:48 PM

$LXRX In Debbane and Exton I trust.

0 · Reply

wildwesttrader Jul. 11 at 4:27 PM

$LXRX good news. We stay above a dollar. The Friday sell off isn’t that bad. I’m feeling good about this.

2 · Reply

York_Oxtiny Jul. 11 at 2:49 PM

$LXRX my best advice to prevent panic selling (especially if you’re a large shareholder)— just monitor the stock price. Don’t monitor your account’s reflection of said stock price. I put 80% of my portfolio into RGLS at $1.69. The day it dipped below $0.90 I could imagine it looking catastrophic for my portfolio— but I didn’t sell. And 3 months later we all know what happened. Also, keep in mind this happens every Friday guys.

2 · Reply

Market Cap	408.49M
Revenue (ttm)	31.08M
Net Income (ttm)	-200.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-644.79%
Debt to Equity Ratio	0.82

Volume	3,259,500
Avg Vol	4,518,864
Day's Range	N/A - N/A
Shares Out	361.49M
Stochastic %K	72%
Beta	1.13
Analysts	Sell
Price Target	$2.58